April 24, 2015
New Data Shows Greater In Vitro Potency for VIBATIV(R) (Telavancin) Against Multidrug-Resistant Gram-Positive Bacteria, Including MRSA, Compared to Alternative Antibiotic Treatments
April 16, 2015
Theravance Biopharma to Present New Data Highlighting in vitro Potency of VIBATIV(R) (telavancin) Against Multidrug-Resistant Gram-Positive Bacteria, Including MRSA, at 2015 ECCMID Conference
April 7, 2015
Theravance Biopharma to Present at the Needham Healthcare Conference
Medicines that make a difference®
We apply our multivalency expertise to discover, develop and commercialize small molecule medicines for significant unmet medical needs.
We pursue a best-in-class strategy designed to discover superior medicines across multiple therapeutic areas.
In some instances, we partner our programs in order to accelerate timelines and better align resources.
Every day at Theravance Biopharma, we think it through, find a way, and get it done so that together with our partners we can bring patients much needed new medicines.
Theravance Biopharma discovers, develops and brings important medicines to patients by: